TUBACEX adapts its Organization to fight COVID-19: Q3 Results
TUBACEX’s sales figure for the first nine months of the year amounts to €389.6 million, which is 18.2% lower than that of the same period last year; while EBITDA stands at €26.4 million, down 42.9%, with a 6.8% margin. These results, determined by the global...The global restructuring of the Tubacex Group will affect 20% of the workforce
The negative evolution of the market over the last few years, with a drop of over 50%, and the coronavirus crisis have prompted the Company to implement a series of urgent industrial reorganization and cost-cutting measures. Specifically, with regards to employment,...TUBACEX holds its Annual Shareholders’ General Meeting overshadowed by COVID-19
The company reveals the main points of its strategy in response to the pandemic. With a focus on prevention, the aim is to guarantee the safety of all its workers, and thereby service continuity for its customers. TUBACEX has dealt with this crisis from a solid...TUBACEX presents its results in a market context dominated by COVID-19
2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.
TUBACEX announces consolidated results and ends 2019 with an EBITDA of €67.1 million
2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.